Medicines for Europe aims at ensuring a patient-centric proactive dialogue on the availability and access of medicines involving all the stakeholders: payers, regulators and supply chain actors.

Medicines shortages can be addressed when multisource alternatives are available.

In order to tackle medicines shortages in a multi-source context, Medicines for Europe believes in an approach that addresses both the root causes of medicines shortages (preventing medicines shortages) and mitigates them once they occur (mitigating medicines shortages).

Medicines for Europe believes in the importance to provide patients timely access to medicines and is committed to provide a safe and continuous supply of medicines as a key public health objective. In this view, Medicines for Europe aims at ensuring a patient-centric proactive dialogue on the availability and access of medicines involving all the stakeholders: payers, regulators and supply chain actors.

Medicines for Europe believes that the medical use of generic medicines should be considered as an opportunity to increase patient access and prevent medicines shortages through increased choice and availability of treatments. Medicines shortages can be addressed when multisource alternatives are available.

Generic medicines have transformed healthcare in Europe by significantly increasing patient access to medicines in an era of rising demands for healthcare services and constrained finances. Over the last ten years, generic medicines have increased access to medicines by over 100% in seven key therapeutic areas without increasing the overall treatment cost.

Drivers of medicines shortages in an off-patent, multi-source sector

Members of Medicines for Europe are highly committed to quality. To achieve this quality, manufacturers comply with stringent regulatory and quality procedures. These procedures are costly and experience has proven that there is an inability of the market to reward the investment on these procedures. Additionally, the extreme pressure on prices due to short-term cost containment measures such as tendering, external reference pricing and payback mechanisms challenge the sustainability of our industry provoking the withdrawal of medicines from the market and increasing the risk of medicines shortages.
In order to tackle medicines shortages in a multi-source context, Medicines for Europe believes in an approach that addresses both the root causes of medicines shortages (preventing medicines shortages) and mitigates them once they occur (mitigating medicines shortages).

**Recommendations to prevent shortages**

**Improve regulatory efficiency**

The EU has high regulatory standards in place which need to be complied with before a medicine can be placed on the market. While we encourage these high standards, Medicines for Europe considers that enhancing regulatory efficiency and fit-for-purpose regulatory measures can foster greater access to and availability of medicines. To increase the efficiency and optimise the regulatory processes to reduce the administrative and cost burden of keeping the medicines on the market, we recommend to implement a flat fee structure for variations, optimise the use of Centralised and Decentralised procedures for generic medicines, increase flexibility to accept different pack sizes or multi-country packs to address market needs, increase use of telematics tool (e.g. FMD, ISO-IDMP, Art. 57, etc.) for communication of changes currently requiring variation submission in large portfolios and lower fees/costs for older molecules that still serve a healthcare need.

**Ensure market predictability**

Generic manufacturing is a competitive business which aims at having efficient operations to minimise costs and offer maximum discounts to payers. To date, the main focus of healthcare policies around generic medicines has been on cutting prices, instead of securing patient access to high-quality medicines. Average price reduction after patent expiry is 50%, increasing further over time up to 80-90%.

Cost-containment measures such as government mandated price reductions, internal and external reference pricing and procurement through tendering, undermine the long-term sustainability of manufacturers while increasing the risk of medicines shortages that ultimately affects patient health. This was also acknowledged by the World Health Organisation (WHO), which stated that there are more appropriate pricing mechanisms for off-patent medicines than external reference pricing (WHO HAI 2011 – Project on medicines availability – External reference Pricing). Similarly, most scientific articles reviewing shortages of generic medicines identify cost-containment measures and policies as the underlying root cause.  

The most extreme examples of medicines shortages can be found in countries which have disproportionate pharmaceutical pricing policies on generic medicines. In Romania, due to inappropriate cost-containment measures (e.g. clawback tax, external reference pricing, etc.), approximately 2,000 generic medicines have been withdrawn from the market over the last two years alone (annex with links for ‘Clawback influence on shortages’ and ‘Statements of Patient Associations regarding shortages’). As a result, Romania has suffered from chronic shortages of essential but inexpensive medicines such as methotrexate.

Medicines for Europe recommends a predictable and sustainable pricing and reimbursement environment that will increase the number of players in the market to reduce the risk of medicines shortages. This can be achieved with measures that avoid retraction of manufacturers from the market. In particular, the implementation of multi-winner/multi-slot tenders – as agreed in the German ‘pharmadialogue’ – guarantees that multiple players are supplying the market and in case one of the manufacturers cannot supply, other manufacturers in the market are able to supply. Furthermore, disproportionate sanctions should be prevented as they promote retraction of manufacturers from the market and increase the risk of供应. In case there are penalties applied to guarantee supply, these should be proportionate to the revenue of manufacturers and applied in accordance with the contract criteria. In Slovakia, under the umbrella of the Article 81 of Directive 2001/83/EC, and to avoid medicines shortages, the government is issuing a legal obligation to manufacturers to supply within 24 hours. In case manufacturers fail to supply, they are subjected to penalties of up to 1 Million Euro. The way in which these penalties are applied (by SKU rather than INN) will lead to disproportionate fines amounting to multiples of generic medicines industry sales which will undermine the sustainability of the pharmaceutical industry and increase the risk of medicines shortages.

Finally, to ensure that the society will continue to benefit from these medicines, it will be important to develop a predictable and sustainable market model. At this moment, generic medicines account for over 56% of the medicines dispensed in Europe at only 22% of the costs, which is only 2-3% of total healthcare budgets.

Address negative healthcare impacts of parallel trade

Parallel exports from Eastern Europe to Western Europe are contributing to availability problems which undermine public health. Slovakia, Czech Republic and Romania are proposing measures to address medicines shortages caused by parallel exports: if a medicine is at risk of experiencing medicines shortages, distributors will have to notify the relevant authorities which will decide whether the medicine can be exported.

Recommendations to mitigate shortages

Specific regulatory measures to mitigate imminent shortage

Medicines for Europe encourages the enforcement of already existing regulatory measures to mitigate medicines shortages when they occur.

Such measures would serve two main purposes, namely to allow the concerned manufacturer to resume its activities in compliance with regulatory requirements within a reasonably short timeframe and to encourage other manufacturers producing a therapeutically equivalent medicine to rapidly supply the market.

16 Article 81 of Directive 2001/83/EC: EU legislation that imposes legal obligation for the marketing authorisation holder to ensure, within the limits of their responsibilities, a continuous supply.
Mitigating the potential impact of medicines shortages through regulatory discretion measures could consist of various elements such as e.g. in the context of a potential supply disruption, flexibility to accept different pack sizes on national level based on decentralised procedure Marketing Authorisation, harmonisation of pack sizes requirements across EU, incentives for medically essential low cost medicines (e.g. lower variation fees/flat fee). Furthermore, incentives to authorise alternative API supplier(s), simplified way of reporting variations, provide re-packaging flexibility to MAH to address shortages and efficient Repeat Use Procedure would be relevant measures to tackle medicines shortages. These measures are consistent with Medicines for Europe’s plea for all possible efficiency gains in the EU regulatory system as outlined in the 42 recommendations of its Regulatory Efficiency report.17

Beyond regulatory mitigation measures, a more fundamental reflection is needed in order to design a new model aimed at balancing maintenance and regulatory fees for essential medicinal products with limited-to-no commercial attractiveness, and where two or less manufacturers supply the market (higher risk of supply disruption).

**Manage available market stock information**

In 2019, a European Medicines Verification System (EMVS) will be in place which could support authorities and manufacturers to better manage supply through the management of the information available in the EMVS. We believe that this system constitutes an opportunity to increase transparency in supply chain for supply chain actors, enabling better management of production and supply.

Currently manufacturers have a legal obligation to notify to 28 different competent authorities of supply disruption due to manufacturing and quality issues. Therefore, Medicines for Europe recommends the use of this system as a European harmonised reporting standard of medicines shortages throughout the supply chain. Despite the importance of having in place a proper and controlled communication system, we believe that the notification and aim of the supply chain actors to tackle medicines shortages should not be punished by exorbitant and disproportionate penalties.

**Conclusions**

In conclusion, Medicines for Europe considers that continuous availability of medicines is a patient-centric shared concern and responsibility of payers, regulators and all supply chain actors. Medicines for Europe believes that preventing and mitigating shortages requires addressing economic causes of shortages, improving regulatory efficiency, more transparency in supply chain and proper and controlled communication.

---

Annex

Clawback and pricing policy influence on medicines shortages in Romania

**Date:** 18th October, 2016

**Press statement:** none

**Media source:** APMGR website

**Subject:** The Ministry of Health’s proposal for a new pricing methodology brings no improvement to generic medicines, which will continue to disappear from the market, leaving patient without essential, affordable pharmaceutical treatment. Thousands of medicines will continue to disappear at a fast path, chronic patients are most affected.


**Date:** 14th October, 2016

**Press statement:** Laurentiu Mihai, executive director of APMGR

**Media source:** hotnews.ro

**Subject:** APMGR asks for a real debate of the pricing policy for medicines, warning that generic medicines continue to be discriminated through double referencing (lowest price in 12 reference countries and 65% of the innovative medicines price). Changing the pricing methodology only for a limited number of medicines, comprised in the WHO list of essential medicines will not solve the medicine availability problem in Romania.


**Date:** 22nd September 2016

**Media source:** digi24.ro

**Press statement:** ARPIM and APMGR

**Subject:** Medicines producers ask for the elimination of clawback tax saying it is a necessary and normal provision given the no-crisis economic context. The savings the state believes will made out of the low prices and over taxation will be surpassed by the treatment expenses.

**Date:** 30th September 2016  
**Media source:** adevarul.ro  
**Subject:** Without a differentiated clawback tax for generic medicines, thousands of medicines will disappear from the market from basic therapeutic areas, such as cardiovascular, digestive and respiratory diseases. Maintaining the same clawback tax for generic and innovative medicines is discriminatory, given that the clawback tax’s fiscal impact is three times higher on generic medicines.  
Link:  

**Date:** 29th July 2016  
**Media source:** hotnews.ro  
**Press statement:** Dragos Damian, president of APMGR  
**Subject:** Medicines producers ask for the elimination of clawback tax. They note that over 2,000 medicines have disappeared from the market and hundreds of patients die each year as they cannot access medicines.  
Link:  

**Date:** 13th May 2016  
**Media source:** cursdeguvernare.ro  
**Press statement:** Dan Zaharescu, Executive President of APRIM  
**Subject:** Over 800,000 patients are at risk to lose their treatments with innovative medicines as 123 medicines will disappear from the market starting July 2016 caused by the Order of Ministry 307/2015. Negative consequences of this Order will be also at economical level.  
Link:  

**Statements of Patient Associations in Romania regarding shortages**

**Date:** 1st March 2016  
**Media source:** site COPAC
Press statement: none

Subject: COPAC draws attention on the serious situation in which the chronic disease patients are as they cannot find the treatment, risking their life.

Link:

Date: 2nd March 2016

Media source: Adevarul

Press statement: Radu Ganescu, President of COPAC

Subject: Ministry of Health initiates discussions with the patient associations. The associations warn that other medicines will be out of the market and patients won’t be able to find them.

Link:

Date: 9th March 2016

Media source: site COPAC

Press statement: Radu Ganescu

Subject: COPAC asked President Iohannis to put the lack of medicines problem on the CSAT agenda of 15th of March.

Link:

Date: 23rd March 2016

Media source: Radio Romania Actualitati

Press statement: Radu Ganescu, President of COPAC

Subject: The patients claim the lack of medicines. The ministry of Health declares he published on order to stop the export.

Link:
http://www.romania-actualitati.ro/pacientii_reclama_lipsa_unui_numar_mare_de_medicamente_din_farmacii-88122
Date: 18th April 2016  
Media source: miscareadeerezistenta.ro  
Press statement: Radu Ganescu  
Subject: Diabetes, multiple scleroses, Parkinson, Lupus patients are in danger because of lack of vital medicines  
Link:  
http://www.miscareaderezistenta.ro/sanatate/28063-insulin%C4%83-madopar-rebif-lips%C4%83

Date: 21st April 2016  
Media source: agerpres.ro  
Press statement: Cezar Irimia (FABC)  
Subject: The President of FABC made a memo to the Ministry of Health to draw attention on the lack of cancer medicines on the market, such as Tamoxifen.  
Link:  

Date: 5th May 2016  
Media source: site COPAC  
Declaratatie de presa: nu  
Subject: COPAC and ATR had a meeting with Victor Ciorbea and its councilors to discuss the serious problem of lack of medicines for chronic diseases.  
Link:  

Date: 20th May 2016  
Media source: site COPAC  
Press statement: Radu Ganescu, President of COPAC  
Subject: COPAC expresses its hope that the new minister will solve the problem of lack of medicines  
Link:  
http://www.copac.ro/declaratie-de-presa-2/
Date: 22nd June 2016  
Media source: site COPAC  
Press statement: Radu Ganescu, President of COPAC  
Subject: COPAC points out the extremely serious situation of lack of medicines on the Romanian market.  
Link:  

Date: 26th July 2016  
Media source: Radio Romania Actualitati  
Press statement: Cezar Irimia (FABC)  
Subject: The Patients Alliance sets alarm bell ringing. Vital medicines are not on the list of compensated and free medicines.  
Link:  
http://www.romania-actualitati.ro/medicamente_vitale_lipsesc_de_pe_listele_compensate_si_gratuite-92331

Date: 16th August 2016  
Media source: radioiasi.ro  
Press statement: Cezar Irimia  
Subject: Call Center launched by APC to point out the lack of medicines in pharmacies  
Link:  

Date: 22nd August 2016  
Media source: Romania Libera  
Press statement: Cezar Irimia, President of APCR  
Subject: APCR remarks that patients don’t have access to compensated medicines in the absence of the publication of therapeutically protocols.
Medicines for Europe

Medicines for Europe (formerly EGA) represents the generic, biosimilar and value added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines for Europe, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members employ 160,000 people at over 350 manufacturing and R&D sites in Europe, and invest up to 17% of their turnover in medical innovation.